An antirheumatic drug used to treat rheumatoid arthritis.
Adalimumab is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to Tumor necrosis factor-alpha, preventing it from activating TNF receptors. Adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. As of 2008 adalimumab has been approved by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012 by the FDA in the disease's management, it has been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's Disease. However, because TNFα is part of the immune system that protects the body from infection, treatment with adalimumab may increase the risk of infections.
The numerical value of adalimumab in Chaldean Numerology is: 9
The numerical value of adalimumab in Pythagorean Numerology is: 5
Images & Illustrations of adalimumab
Translations for adalimumab
From our Multilingual Translation Dictionary
Get even more translations for adalimumab »
Find a translation for the adalimumab definition in other languages:
Select another language: